Patent details

Basic Information

Publication number:

EP3380121

PCT Application Number:

US2016063557

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP168692556

PCT Publication Number:

WO2017091706

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ACTRII ANTAGONIST FOR USE IN TREATING EYE DISORDERS

French Title of Invention:

ACTRII ANTAGONISTE POUR L'UTILISATION DANS LE TRAITEMENT DES TROUBLES OCULAIRES

German Title of Invention:

ACTRII-ANTAGONIST ZUR VERWENDUNG IN DER BEHANDLUNG VON AUGENERKRANKUNGEN

SPC Number:

Dates

Filing date:

23/11/2016

Grant date:

20/12/2023

EP Publication Date:

03/10/2018

PCT Publication Date:

01/06/2017

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

20/12/2023

EP B1 Publication Date:

20/12/2023

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

23/11/2024

Expiration date:

23/11/2036

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

13/12/2023

 

 

Name:

Acceleron Pharma Inc.

Address:

128 Sidney Street, Cambridge, MA 02139, United States (US)

Inventor

1

Name:

SHERMAN, Matthew, L.

Address:

United States (US)

2

Name:

ATTIE, Kenneth, M.

Address:

United States (US)

Priority

Priority Number:

201562258934 P

Priority Date:

23/11/2015

Priority Country:

United States (US)

Classification

IPC classification:

A61K 39/395; A61K 38/18; A61P 27/02;

Publication

European Patent Bulletin

Issue number:

202351

Publication date:

20/12/2023

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages